Janumet XR is a fixed-dose combination diabetes drug that contains sitagliptin (100mg) and metformin hydrochloride (1000mg) as its active ingredients. The core tablet (made of extended-release metformin) is coated with an immediate-release layer of sitagliptin. Sitagliptin is a type of dipeptidyl peptidase-4 (DPP-4) inhibitor that slows the inactivation of incretin. Metformin hydrochloride (HCl), on the other hand, is a biguanide that helps reduce postprandial (and basal) plasma glucose. The tablets come in the dosage of 100mg/1000mg. Additionally, Janumet XR is available in lower dosage strengths of 50mg/500mg and 50mg/1000mg.
This medication is prescribed for diabetic patients (particularly those with type II diabetes mellitus) to improve glycemic control. Janumet XR is commonly used in conjunction with other non-pharmacological interventions such as exercise and diet. Due to its unique mode of action, Janumet XR is not effective in the management of type I diabetes and diabetic ketoacidosis. The effects of this drug in pediatrics under 18 years of age are not well studied; therefore, the use of Janumet XR is only recommended for adult patients.
Use Janumet XR to improve glycemic control. This combination drug eliminates the hassle of taking two separate medicines, potentially improving patient adherence.